Roche giant buys IQuum for 450 million dollars

The deal of the month and maybe even bigger in Switzerland is the acquisition of IQuum by pharmaceutical giant, Roche. The Basel based company announced today the 450 million dollar ( 328 million euros) deal.

IQuum is an American molecular diagnostics testing firm tied to pharmaceutical industry. The private owned company is based in Boston, Massachusetts and brags about leading the world in fast testing thanks to some advanced technologies. It does not even need specialized personal to perform sophisticated tests. IQuum has developed a uniform system for nucleic acid, protein and cellular tests that revealed complete information. 

“With this deal we further strengthen our molecular diagnostics offering with cutting edge technology and products that serve the point of care segment,” stated Roche's Diagnostics COO, Roland Diggelamnn. The deal will set back IQuum 275 million in advance and 175 million in addition, but tied to some milestones.

Roche Diagnostics is a division of Hoffman La Roche which manufactures medical equipment. The giant Swiss company also embeds Roche Molecular Diagnostics, Roche Tissue Diagnostics, Roche Professional Diagnostics, Roche Applied Science and now IQuum. Hoffman La Roche is a global leading company operating in U.S, South America, Asia, Europe and Africa. It has 26 manufacturing sites around the world.